{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:17:54Z","timestamp":1788419874892,"version":"build-2803163510"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"5","funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT148586"],"award-info":[{"award-number":["PJT148586"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012118","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","award":["IA-039"],"award-info":[{"award-number":["IA-039"]}],"id":[{"id":"10.13039\/100012118","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Longo Family Cancer Foundation"},{"name":"Ira Schneider Memorial Cancer Research Foundation"},{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Longo Family Cancer Foundation"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chimeric antigen receptor (CAR) technology has revolutionized B-cell malignancy treatment by enabling T cells to effectively recognize and target lineage-specific surface antigens. However, CAR T cells show limited efficacy against myeloid neoplasms and solid tumors due to challenges in identifying suitable surface targets. In this study, we present a CAR targeting the intracellular WT1 oncoprotein, cross-presented by surface HLA class II (HLA-II) alleles. WT1-CAR T cells, derived from an antibody raised solely against a WT1 peptide, recognized the WT1330\u2013348 peptide promiscuously presented by 18 out of 20 tested HLA-II alleles, overcoming traditional HLA restrictions. WT1-CAR T cells specifically recognized leukemic cells in a WT1- and HLA-II\u2013dependent manner and mediated an antitumor response in vitro and in vivo. This approach broadens CAR-targetable antigens beyond traditional HLA restrictions and offers a promising therapeutic option to a wide and genetically diverse patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Leveraging the promiscuous binding of HLA-II\u2013peptide complexes, we developed a CAR T-cell approach targeting an intracellular oncoprotein WT1 presented across diverse HLA-II families. Our study establishes a framework for CAR therapies against intracellular antigens, extending potential CAR T-cell applications to new cancer types and patient populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0230","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:32:42Z","timestamp":1786714362000},"page":"813-828","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1815-4393","authenticated-orcid":false,"given":"Evey Y.F.","family":"Zheng","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."},{"name":"2Department of Immunology, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9513-0233","authenticated-orcid":false,"given":"Chung-Hsi","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."},{"name":"2Department of Immunology, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8440-6144","authenticated-orcid":false,"given":"Toshiki","family":"Ochi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5548-6519","authenticated-orcid":false,"given":"Yota","family":"Ohashi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."},{"name":"2Department of Immunology, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5932-6544","authenticated-orcid":false,"given":"Fumie","family":"Ihara","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4484-0689","authenticated-orcid":false,"given":"Saori","family":"Fukao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3239-1152","authenticated-orcid":false,"given":"Yusuke","family":"Ito","sequence":"additional","affiliation":[{"name":"3Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6567-6234","authenticated-orcid":false,"given":"Giselle M.","family":"Boukhaled","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1842-7371","authenticated-orcid":false,"given":"Ben X.","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3456-1027","authenticated-orcid":false,"given":"Dong-Hoon","family":"Han","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."},{"name":"2Department of Immunology, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0930-7272","authenticated-orcid":false,"given":"Xinyu","family":"Wei","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."},{"name":"2Department of Immunology, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5942-9392","authenticated-orcid":false,"given":"Priyanka","family":"Yolmo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1846-7453","authenticated-orcid":false,"given":"Brian D.","family":"Burt","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5808-2252","authenticated-orcid":false,"given":"Kayoko","family":"Saso","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1392-5681","authenticated-orcid":false,"given":"Yukiko","family":"Matsunaga","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1177-0225","authenticated-orcid":false,"given":"Dalam","family":"Ly","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6216-6730","authenticated-orcid":false,"given":"Yuki","family":"Kagoya","sequence":"additional","affiliation":[{"name":"3Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-7057","authenticated-orcid":false,"given":"Marcus O.","family":"Butler","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."},{"name":"2Department of Immunology, University of Toronto, Toronto, Canada."},{"name":"4Department of Medicine, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9089-8816","authenticated-orcid":false,"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."},{"name":"4Department of Medicine, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-4754","authenticated-orcid":false,"given":"Naoto","family":"Hirano","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 1 , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 1 , , Toronto, Canada."},{"name":"2Department of Immunology, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2026090303075685500_bib1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"2026090303075685500_bib2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090303075685500_bib3","doi-asserted-by":"publisher","first-page":"eabc8697","DOI":"10.1126\/science.abc8697","article-title":"Targeting a neoantigen derived from a common TP53 mutation","volume":"371","author":"Hsiue","year":"2021","journal-title":"Science"},{"key":"2026090303075685500_bib4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fmed.2017.00018","article-title":"MAGE-A antigens and cancer immunotherapy","volume":"4","author":"Zajac","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"2026090303075685500_bib5","doi-asserted-by":"publisher","first-page":"18851","DOI":"10.1038\/srep18851","article-title":"Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy","volume":"6","author":"Raman","year":"2016","journal-title":"Sci Rep"},{"key":"2026090303075685500_bib6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3389\/fimmu.2015.00464","article-title":"Endogenous antigen presentation of MHC class II epitopes through non-autophagic pathways","volume":"6","author":"Leung","year":"2015","journal-title":"Front Immunol"},{"key":"2026090303075685500_bib7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation","volume":"15","author":"Roche","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2026090303075685500_bib8","doi-asserted-by":"publisher","first-page":"15244","DOI":"10.1038\/ncomms15244","article-title":"HLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway","volume":"8","author":"Yamashita","year":"2017","journal-title":"Nat Commun"},{"key":"2026090303075685500_bib9","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1038\/s41598-018-22931-4","article-title":"Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP84Gly","volume":"8","author":"Anczurowski","year":"2018","journal-title":"Sci Rep"},{"key":"2026090303075685500_bib10","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","article-title":"Biological consequences of MHC-II expression by tumor cells in cancer","volume":"25","author":"Axelrod","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026090303075685500_bib11","doi-asserted-by":"publisher","first-page":"7932","DOI":"10.4049\/jimmunol.179.11.7932","article-title":"Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients","volume":"179","author":"Kudela","year":"2007","journal-title":"J Immunol"},{"key":"2026090303075685500_bib12","doi-asserted-by":"publisher","first-page":"eaat0687","DOI":"10.1126\/sciimmunol.aat0687","article-title":"CD4+ T cell\u2013mediated HLA class II cross-restriction in HIV controllers","volume":"3","author":"Galperin","year":"2018","journal-title":"Sci Immunol"},{"key":"2026090303075685500_bib13","doi-asserted-by":"publisher","first-page":"831822","DOI":"10.3389\/fimmu.2022.831822","article-title":"Promiscuity of peptides presented in HLA-DP molecules from different immunogenicity groups is associated with T-cell cross-reactivity","volume":"13","author":"Laghmouchi","year":"2022","journal-title":"Front Immunol"},{"key":"2026090303075685500_bib14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/1074-7613(94)90049-3","article-title":"Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells","volume":"1","author":"Denzin","year":"1994","journal-title":"Immunity"},{"key":"2026090303075685500_bib15","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.4049\/jimmunol.1100255","article-title":"An insertion mutant in DQA1*0501 restores susceptibility to HLA-DM: implications for disease associations","volume":"187","author":"Hou","year":"2011","journal-title":"J Immunol"},{"key":"2026090303075685500_bib16","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/ni.1780","article-title":"Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation","volume":"10","author":"Fallang","year":"2009","journal-title":"Nat Immunol"},{"key":"2026090303075685500_bib17","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","article-title":"Safety and persistence of WT1-specific T-cell receptor gene\u2212transduced lymphocytes in patients with AML and MDS","volume":"130","author":"Tawara","year":"2017","journal-title":"Blood"},{"key":"2026090303075685500_bib18","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"key":"2026090303075685500_bib19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1348-0421.2008.00080.x","article-title":"A WT1 protein-derived, naturally processed 16-mer peptide, WT1332, is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4+ T cells","volume":"52","author":"Fujiki","year":"2008","journal-title":"Microbiol Immunol"},{"key":"2026090303075685500_bib20","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/leu.2012.248","article-title":"Identification of a Wilms\u2019 tumor 1-derived immunogenic CD4+ T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes","volume":"27","author":"Anguille","year":"2013","journal-title":"Leukemia"},{"key":"2026090303075685500_bib21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/CJI.0b013e3182873581","article-title":"HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells","volume":"36","author":"Lin","year":"2013","journal-title":"J Immunother"},{"key":"2026090303075685500_bib22","first-page":"1251","article-title":"Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells","volume":"35","author":"Katsuhara","year":"2015","journal-title":"Anticancer Res"},{"key":"2026090303075685500_bib23","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.4049\/jimmunol.178.9.5727","article-title":"Human TCR-binding affinity is governed by MHC class restriction","volume":"178","author":"Cole","year":"2007","journal-title":"J Immunol"},{"key":"2026090303075685500_bib24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-immunol-032414-112334","article-title":"T cell antigen receptor recognition of antigen-presenting molecules","volume":"33","author":"Rossjohn","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"2026090303075685500_bib25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"2026090303075685500_bib26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3324\/haematol.2017.175083","article-title":"Comparative profiling of HLA-DR and HLA-DQ associated factor VIII peptides presented by monocyte-derived dendritic cells","volume":"103","author":"Peyron","year":"2018","journal-title":"Haematologica"},{"key":"2026090303075685500_bib27","doi-asserted-by":"publisher","first-page":"1067463","DOI":"10.3389\/fimmu.2022.1067463","article-title":"HLA variants have different preferences to present proteins with specific molecular functions which are complemented in frequent haplotypes","volume":"13","author":"Karnaukhov","year":"2022","journal-title":"Front Immunol"},{"key":"2026090303075685500_bib28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399407000336","article-title":"The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis","volume":"9","author":"Ariyaratana","year":"2007","journal-title":"Expert Rev Mol Med"},{"key":"2026090303075685500_bib29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/cancers15020393","article-title":"WT1 Trio peptide-based cancer vaccine for rare cancers expressing shared target WT1","volume":"15","author":"Oji","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026090303075685500_bib30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13045-025-01661-x","article-title":"WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome","volume":"18","author":"Berneman","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026090303075685500_bib31","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/leu.2016.373","article-title":"Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen","volume":"31","author":"Rafiq","year":"2017","journal-title":"Leukemia"},{"key":"2026090303075685500_bib32","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood-2017-08-802926","article-title":"Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination","volume":"132","author":"Akahori","year":"2018","journal-title":"Blood"},{"key":"2026090303075685500_bib33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jmb.2015.12.002","article-title":"Structure of a TCR-mimic antibody with target predicts pharmacogenetics","volume":"428","author":"Ataie","year":"2016","journal-title":"J Mol Biol"},{"key":"2026090303075685500_bib34","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41586-023-06706-0","article-title":"Targeting of intracellular oncoproteins with peptide-centric CARs","volume":"623","author":"Yarmarkovich","year":"2023","journal-title":"Nature"},{"key":"2026090303075685500_bib35","first-page":"39","article-title":"Structural insights into HLA-DM mediated MHC II peptide exchange","volume":"13","author":"Painter","year":"2011","journal-title":"Curr Top Biochem Res"},{"key":"2026090303075685500_bib36","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.4049\/jimmunol.0903655","article-title":"Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity","volume":"184","author":"Sidney","year":"2010","journal-title":"J Immunol"},{"key":"2026090303075685500_bib37","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1073\/pnas.92.14.6567","article-title":"Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DR beta chain","volume":"92","author":"Davenport","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090303075685500_bib38","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1002\/1521-4141(200209)32:9&lt;2510::AID-IMMU2510&gt;3.0.CO;2-Q","article-title":"Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor","volume":"32","author":"Sant\u2019Angelo","year":"2002","journal-title":"Eur J Immunol"},{"key":"2026090303075685500_bib39","doi-asserted-by":"publisher","first-page":"13279","DOI":"10.1073\/pnas.0403371101","article-title":"A hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition","volume":"101","author":"Zavala-Ruiz","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090303075685500_bib40","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/s0968-0896(01)00434-5","article-title":"Major histocompatibility complex class II binding characteristics of peptoid-peptide hybrids","volume":"10","author":"de Haan","year":"2002","journal-title":"Bioorg Med Chem"},{"key":"2026090303075685500_bib41","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.4049\/jimmunol.178.11.7181","article-title":"Cooperativity of hydrophobic anchor interactions: evidence for epitope selection by MHC class II as a folding process","volume":"178","author":"Ferrante","year":"2007","journal-title":"J Immunol"},{"key":"2026090303075685500_bib42","first-page":"4773","article-title":"Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles","volume":"61","author":"Kobayashi","year":"2001","journal-title":"Cancer Res"},{"key":"2026090303075685500_bib43","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"2026090303075685500_bib44","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/gt.2008.90","article-title":"Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition","volume":"15","author":"Yang","year":"2008","journal-title":"Gene Ther"},{"key":"2026090303075685500_bib45","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"2026090303075685500_bib46","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41587-021-00836-4","article-title":"Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells","volume":"39","author":"Sugata","year":"2021","journal-title":"Nat Biotechnol"},{"key":"2026090303075685500_bib47","doi-asserted-by":"publisher","first-page":"e30229","DOI":"10.1371\/journal.pone.0030229","article-title":"Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help","volume":"7","author":"Butler","year":"2012","journal-title":"PLoS One"},{"key":"2026090303075685500_bib48","doi-asserted-by":"publisher","first-page":"101643","DOI":"10.1016\/j.xpro.2022.101643","article-title":"Mass cytometry immunostaining protocol for multiplexing clinical samples","volume":"3","author":"Gadalla","year":"2022","journal-title":"STAR Protoc"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0230\/3821223\/bcd-25-0230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/5\/813\/3824943\/bcd-25-0230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/5\/813\/3824943\/bcd-25-0230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:08:04Z","timestamp":1788419284000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/5\/813\/787648\/CAR-T-Cells-Targeting-an-Intracellular-Leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,8,14]]},"published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0230","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}